Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations

Core Insights - Ocumetics Technology Corp. announced positive one-month results from Group 1 of its first-in-human clinical study for the Ocumetics Accommodating Intraocular Lens, showing promising visual outcomes [1][4][5] Group 1 Surgery Results - Group 1 surgeries were completed in August and September 2025, with all patients showing Corrected Distance Visual Acuity (CDVA) between 20/32 and 20/25 after one month [2][3] - The visual gains observed are particularly encouraging given that patients began the study with significantly impaired distance vision due to cataracts [4] Company Statements - The President and CEO expressed excitement over the results, noting that they have met or exceeded internal expectations and demonstrate the transformative potential of the Ocumetics Lens [4][6] - The Chief Medical Officer highlighted the remarkable achievement of 20/32 or better vision shortly after surgery, emphasizing the lens's optical quality and stability [5] Future Plans - Planning for Group 2 surgeries is currently underway, with updates expected in the coming weeks [7] - The company aims to maintain momentum as it progresses to subsequent patient groups [6] Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, aiming to transform ophthalmology with innovative intraocular lenses and vision-enhancing technologies [8][9]